Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Intraperitoneal Triferic in PD Patients
NCT02909153Phase 1Completed
- Sponsor
- Rockwell Medical
- Start
- Jan 2017
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
01
Overview
Phase 1, randomised, open-label trial of ferric pyrophosphate in anemia (2 arms), sponsored by Rockwell Medical. Primary endpoints: Maximum Concentration of Serum Total Iron After Intraperitoneal Administration at 12 hours, Area Under the Concentration Curve Last of Serum Total Iron After Intraperitoneal Administration at 12 hours and 4 more. Started Jan 2017; status: completed.
02
Drugs
ferric pyrophosphate
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02909153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909153.